Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Allogeneic hematopoietic stem cell transplantation (HSCT) has evolved into an effective
adoptive cellular immunotherapy for the treatment of a number of cancers. The …

Following allogeneic hematopoietic cell transplantation (allo-HCT), the gastrointestinal (GI)
tract is frequently affected by acute graft-versus-host disease (aGVHD), the pathophysiology …

The key immunologic signatures associated with clinical outcomes after posttransplant
cyclophosphamide (PTCy)-based HLA-haploidentical (haplo) and HLA-matched bone …

Graft-versus-host disease (GVHD) remains a significant complication of allogeneic bone
marrow transplantation (allo-BMT). Acute GVHD is mediated by immunocompetent donor T …

Destruction of the host intestinal epithelium by donor effector T cell populations is a hallmark
of graft-versus-host disease (GVHD), but the underlying mechanisms remain obscure. We …

Cytokine-induced killer (CIK) cells are ex vivo–expanded T lymphocytes expressing both
natural killer (NK)–and T-cell markers. CIK cells are cytotoxic against autologous and …

Purpose: Immune-mediated graft-versus-tumor (GVT) effects can occur after allogeneic
hematopoietic stem cell transplantation (HSCT), but GVT is tightly linked to its main …

The clinical goal of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is to
minimize GVHD while maintaining GvL. Here, we show that interferon γ receptor-deficient …

Antigen-presenting cells (APCs) integrate signals emanating from local pathology and
program appropriate T cell responses. In allogeneic hematopoietic stem cell transplantation …